Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Bo Åhrén, Stephen L. Atkin, G. Charpentier, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 9, pp. 2210-2219
Open Access | Times Cited: 110

Showing 26-50 of 110 citing articles:

The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
Merlin C. Thomas, Melinda T. Coughlan, Mark E. Cooper
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 253-273
Open Access | Times Cited: 33
Approach to the Patient: Management of the Post–Bariatric Surgery Patient With Weight Regain
Nawfal W. Istfan, Marine Lipartia, Wendy Anderson, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 106, Iss. 1, pp. 251-263
Open Access | Times Cited: 65
The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity
Chrysi Koliaki, Stavros Liatis, Μaria Dalamaga, et al.
Current Obesity Reports (2020) Vol. 9, Iss. 3, pp. 255-271
Open Access | Times Cited: 62
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
Ildiko Lingvay, Thomas K. Hansen, Stanislava Macura, et al.
BMJ Open Diabetes Research & Care (2020) Vol. 8, Iss. 2, pp. e001706-e001706
Open Access | Times Cited: 54
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
Sara Volpe, Giuseppe Lisco, Davide Racaniello, et al.
Nutrients (2022) Vol. 14, Iss. 12, pp. 2414-2414
Open Access | Times Cited: 36
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh, Kyung Mook Choi
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3384-3384
Open Access | Times Cited: 22
Enteroendocrine cell regulation of the gut-brain axis
Joshua R. Barton, Anne Londregan, Tyler D. Alexander, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 19
Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review
Brandon Stretton, Joshua G. Kovoor, Stephen Bacchi, et al.
Internal Medicine Journal (2023) Vol. 53, Iss. 8, pp. 1311-1320
Open Access | Times Cited: 17
GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment
Justin W. L. Wan, Caesar Ferrari, Micheal Tadros
Gastroenterology Insights (2024) Vol. 15, Iss. 1, pp. 191-212
Open Access | Times Cited: 8
Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?
Matthew L. Magruder, David Jacofsky, Bryan D. Springer, et al.
The Journal of Arthroplasty (2024) Vol. 39, Iss. 2, pp. 277-282
Closed Access | Times Cited: 7
Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials
Sharath Kommu, Richard L. Berg
Obesity Reviews (2024) Vol. 25, Iss. 9
Open Access | Times Cited: 6
Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ruaa Al Sakka Amini, Abdellatif Ismail, Maysarah Mahdi Alaqrabawi, et al.
Cureus (2024)
Open Access | Times Cited: 6
Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Sanjay Kalra, Ashok Kumar Das, Rakesh Sahay, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1645-1717
Open Access | Times Cited: 45
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Matthew R. Hayes, Tito Borner, Bart C. De Jonghe
Diabetes (2021) Vol. 70, Iss. 9, pp. 1956-1961
Open Access | Times Cited: 40
Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction
Elia C. El Hajj, Milad El Hajj, Brandon Sykes, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 21
Open Access | Times Cited: 37
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
Ryosuke Ono, Kenichi Furihata, Yoshihiko Ichikawa, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 805-814
Open Access | Times Cited: 24
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
Vanita R. Aroda, Robert Bauer, Erik Christiansen, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1338-1350
Open Access | Times Cited: 23
Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial
Yuqin Zhang, Zhihua Qu, Ting Lu, et al.
Nutrients (2023) Vol. 15, Iss. 3, pp. 556-556
Open Access | Times Cited: 15
The antiemetic actions of GIP receptor agonism
Tito Borner, Bart C. De Jonghe, Matthew R. Hayes
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 4, pp. E528-E536
Closed Access | Times Cited: 5
Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials
Cyrus Desouza, Bertrand Cariou, Satish K. Garg, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 105, Iss. 2, pp. 543-556
Open Access | Times Cited: 38
Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
Tito Borner, Ian C. Tinsley, Robert P. Doyle, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 542-556
Open Access | Times Cited: 31
Obesity pharmacotherapy: incretin action in the central nervous system
Geke Aline Boer, Debbie L. Hay, Alexander Tups
Trends in Pharmacological Sciences (2022) Vol. 44, Iss. 1, pp. 50-63
Closed Access | Times Cited: 22
Obesity and diabetes: the final frontier
Marc Rendell
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 1, pp. 81-94
Closed Access | Times Cited: 12
Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
Caterina Formichi, Walter Baronti, Giovanni Gennaro, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 11, pp. 2679-2690
Open Access | Times Cited: 4
Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes
Sri Ram Charan Gundapaneni, Rithwik Goud Burri, Reigetsu Kaku, et al.
Cureus (2025)
Open Access

Scroll to top